Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
Public ClinicalTrials.gov record NCT07227818. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
Study identification
- NCT ID
- NCT07227818
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Neurocrine Biosciences
- Industry
- Enrollment
- 560 participants
Conditions and interventions
Conditions
Interventions
- NBI-1117568 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 15, 2025
- Primary completion
- Jun 30, 2029
- Completion
- Jun 30, 2029
- Last update posted
- May 14, 2026
2025 – 2029
United States locations
- U.S. sites
- 18
- U.S. states
- 7
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Neurocrine Clinical Site | Garden Grove | California | 92845 | Recruiting |
| Neurocrine Clinical Site | La Habra | California | 90631 | Recruiting |
| Neurocrine Clinical Site | Lemon Grove | California | 91945 | Recruiting |
| Neurocrine Clinical Site | Oceanside | California | 92056 | Recruiting |
| Neurocrine Clinical Site | West Hills | California | 91307 | Recruiting |
| Neurocrine Clinical Site | Hollywood | Florida | 33024 | Recruiting |
| Neurocrine Clinical Site | Maitland | Florida | 32751 | Recruiting |
| Neurocrine Clinical Site | Miami | Florida | 33122 | Recruiting |
| Neurocrine Clinical Site | Miami | Florida | 33155 | Recruiting |
| Neurocrine Clinical Site | Tampa | Florida | 33629 | Recruiting |
| Neurocrine Clinical Site | West Palm Beach | Florida | 33024 | Recruiting |
| Neurocrine Clinical Site | Atlanta | Georgia | 30318 | Recruiting |
| Neurocrine Clinical Site | Boston | Massachusetts | 02116 | Recruiting |
| Neurocrine Clinical Site | Flowood | Mississippi | 39232 | Recruiting |
| Neurocrine Clinical Site | Cedarhurst | New York | 11516 | Recruiting |
| Neurocrine Clinical Site | New York | New York | 10029 | Recruiting |
| Neurocrine Clinical Site | New York | New York | 10036 | Recruiting |
| Neurocrine Clinical Site | Bellevue | Washington | 98007 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07227818, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 14, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07227818 live on ClinicalTrials.gov.